Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 3
1996 1
1997 1
1998 4
1999 6
2000 8
2001 10
2002 8
2003 5
2004 6
2005 9
2006 14
2007 21
2008 13
2009 14
2010 14
2011 15
2012 27
2013 14
2014 18
2015 21
2016 23
2017 15
2018 15
2019 18
2020 17
2021 28
2022 26
2023 19
2024 18
2025 19
2026 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Did you mean ali el escorial criteria (1 results)?
Diagnostic criteria for amyotrophic lateral sclerosis.
Timmins HC, Thompson AE, Kiernan MC. Timmins HC, et al. Curr Opin Neurol. 2024 Oct 1;37(5):570-576. doi: 10.1097/WCO.0000000000001302. Epub 2024 Jul 22. Curr Opin Neurol. 2024. PMID: 39037015 Review.
PURPOSE OF REVIEW: The present review will discuss the evolution of diagnostic criteria for amyotrophic lateral sclerosis (ALS) and biomarker considerations. RECENT FINDINGS: To address the limitations of existing ALS diagnostic criteria, a consortium …
PURPOSE OF REVIEW: The present review will discuss the evolution of diagnostic criteria for amyotrophic lateral sclerosis (ALS …
Progressive Muscular Atrophy.
Liewluck T, Saperstein DS. Liewluck T, et al. Neurol Clin. 2015 Nov;33(4):761-73. doi: 10.1016/j.ncl.2015.07.005. Neurol Clin. 2015. PMID: 26515620 Review.
Patients with subclinical upper motor neuron involvement do not fulfill the revised El Escorial criteria to participate in amyotrophic lateral sclerosis clinical trials. ...
Patients with subclinical upper motor neuron involvement do not fulfill the revised El Escorial criteria to participate …
Characterising ALS disease progression according to El Escorial and Gold Coast criteria.
de Jongh AD, Braun N, Weber M, van Es MA, Masrori P, Veldink JH, van Damme P, van den Berg LH, van Eijk RPA. de Jongh AD, et al. J Neurol Neurosurg Psychiatry. 2022 Aug;93(8):865-870. doi: 10.1136/jnnp-2022-328823. Epub 2022 Jun 2. J Neurol Neurosurg Psychiatry. 2022. PMID: 35654584
BACKGROUND: The Gold Coast criteria (GCC) have been proposed as a means of selecting patients for amyotrophic lateral sclerosis (ALS) clinical trials. ...Therefore, the revised El Escorial criteria (rEEC) were supplemented with a 'Gold Coast …
BACKGROUND: The Gold Coast criteria (GCC) have been proposed as a means of selecting patients for amyotrophic lateral sclerosis (A …
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model.
Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, Körner S, Ringer TM, Rödiger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chiò A, Hardiman O, Moons KGM, Veldink JH, van den Berg LH. Westeneng HJ, et al. Lancet Neurol. 2018 May;17(5):423-433. doi: 10.1016/S1474-4422(18)30089-9. Epub 2018 Mar 26. Lancet Neurol. 2018. PMID: 29598923 Free article.
All patients were diagnosed in the centres after excluding other diagnoses and classified according to revised El Escorial criteria. We assessed 16 patient characteristics as potential predictors of a composite survival outcome (time between onset of symptoms …
All patients were diagnosed in the centres after excluding other diagnoses and classified according to revised El Escorial …
Prognostic factors in ALS: A critical review.
Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG; Eurals Consortium. Chiò A, et al. Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23. doi: 10.3109/17482960802566824. Amyotroph Lateral Scler. 2009. PMID: 19922118 Free PMC article.
We have performed a systematic review to summarize current knowledge concerning factors related to survival in ALS and to evaluate the implications of these data for clinical trials design. The median survival time from onset to death ranges from 20 to 48 months, but 10-20 …
We have performed a systematic review to summarize current knowledge concerning factors related to survival in ALS and to evaluate th …
Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.
Witzel S, Maier A, Steinbach R, Grosskreutz J, Koch JC, Sarikidi A, Petri S, Günther R, Wolf J, Hermann A, Prudlo J, Cordts I, Lingor P, Löscher WN, Kohl Z, Hagenacker T, Ruckes C, Koch B, Spittel S, Günther K, Michels S, Dorst J, Meyer T, Ludolph AC; German Motor Neuron Disease Network (MND-NET). Witzel S, et al. JAMA Neurol. 2022 Feb 1;79(2):121-130. doi: 10.1001/jamaneurol.2021.4893. JAMA Neurol. 2022. PMID: 35006266 Free PMC article. Clinical Trial.
Final analyses included 324 patients with ALS comprising 194 patients who started intravenous edaravone treatment (141 received 4 consecutive treatment cycles; 130 matched) and 130 propensity score-matched patients with ALS receiving standard therapy. All patients …
Final analyses included 324 patients with ALS comprising 194 patients who started intravenous edaravone treatment (141 received 4 co …
A revision of the El Escorial criteria - 2015.
Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J; WFN Research Group On ALS/MND. Ludolph A, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-2. doi: 10.3109/21678421.2015.1049183. Epub 2015 Jun 29. Amyotroph Lateral Scler Frontotemporal Degener. 2015. PMID: 26121170 No abstract available.
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Writing Group, et al. Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15. Lancet Neurol. 2017. PMID: 28522181 Clinical Trial.
Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the revised El Escorial criteria, who met a select set of inclusion criteria showed a greater magnitude of effect tha …
Post-hoc analysis of these data revealed that patients in an early stage with definite or probable diagnosis of ALS, defined by the r …
The revised El Escorial criteria "clinically probable laboratory supported ALS"-once a promising now a superfluous category?
Braun N, Macklin EA, Sinani E, Sherman A, Weber M; Pooled Resource Open-Access ALS Clinical Trials Consortium. Braun N, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2020 Feb;21(1-2):24-28. doi: 10.1080/21678421.2019.1666875. Epub 2019 Sep 27. Amyotroph Lateral Scler Frontotemporal Degener. 2020. PMID: 31561715
Over the past two decades, the El Escorial criteria (EEC) have been used as eligibility criteria in major randomized controlled trials. ...Recently, Edaravone has been licensed in several countries for the treatment of ALS based on a randomized …
Over the past two decades, the El Escorial criteria (EEC) have been used as eligibility criteria in major random …
384 results